RE: Unaudited interims to Dec 31st12 Mar 2025 15:38
quite silverblade. i am possibly one of them! clearly we have a basket case of shares here. i honestly dont think any of them are lemons. this was an incredibly ambitious project very sensibly split into 3 different companies. maybe they were over confident at the beginning. case by case ekf is the least interesting to me at the moment. although hopefully baines has something more productive to say on their current and future situation. i came to these stocks fairly recently so have not suffered quite as heavily as longer term holders. £100,000,000 has been invested in renx i believe so far. without any serious competition this looks like a home run to me barring intervention from the fed and its governors. they have ****ed off the market more than boo which is quite an achievement! i dont know what mistakes have been made in the past if any. its the kind of stock that should have been under the umbrella of a big pharma rather than a cash strapped microcap. for all the drama and soul searching it would be very odd not to romp home now. vrci has had a promo out this year, which i cant seem to locate and its not even on their own website. the trouble with some of these company biotech ceo ‘s is they arent really your normal ceo. they are scientists first and on a mission. sue barrington charming and clever as she is seems to be a bit other worldly and disconnected from the business side of affairs with absolutely no stress hinted at about the current sp, although it was climbing steadily at the time of video earlier this year. again its a cracking (american)venture and no doubt it is also on the way, providing the delayed payment comes through with final approval. possibly unlucky to be caught up in the political turmoil at this stage of their development, although it could be worse. ekf is my smallest holding, but got conned by all the broker targets saying the diagnostics side underlined the sp at 30p. obviously bs. they must have invested a fortune in the as yet unproductive enzyme business. they just seem so unprepared with it. we’ve built the state of the art plant, now what? o yes customers . very odd way to run a business. with luck they will get bought out and put an end to this nonsense. diagnostics is going to play an increasingly mammoth part in the future of medicine for sure. improving outlook for patient care and extremely cost effective, we are so close with these companies despite what the market portrays.